Literature DB >> 15950439

In vitro activity of linezolid against multidrug-resistant Mycobacterium tuberculosis isolates.

Zayre Erturan1, Meltem Uzun.   

Abstract

Information in the literature regarding the activity of linezolid against multidrug-resistant (MDR) Mycobacterium tuberculosis strains is scarce. We therefore tested the in vitro activity of this drug against 39 MDR M. tuberculosis strains isolated from clinical specimens using the Bactec 460 TB system. All strains were inhibited by < or = 8 mg/L (minimum inhibitory concentration (MIC); MIC50 = 4 mg/L, MIC90 = 8 mg/L). Although the MIC values are higher than in other studies, based on proposed breakpoints all strains were found to be susceptible to linezolid. Further investigations to prove its usefulness in the treatment of MDR tuberculosis should be carried out.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950439     DOI: 10.1016/j.ijantimicag.2005.03.006

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  4 in total

1.  In Vitro and In Vivo Activity of Oxazolidinone Candidate OTB-658 against Mycobacterium tuberculosis.

Authors:  Shaochen Guo; Bin Wang; Lei Fu; Xi Chen; Weiyan Zhang; Haihong Huang; Yu Lu
Journal:  Antimicrob Agents Chemother       Date:  2021-08-16       Impact factor: 5.191

2.  Linezolid for drug-resistant pulmonary tuberculosis.

Authors:  Bhagteshwar Singh; Derek Cocker; Hannah Ryan; Derek J Sloan
Journal:  Cochrane Database Syst Rev       Date:  2019-03-20

3.  Compassionate Use of Contezolid for the Treatment of Tuberculous Pleurisy in a Patient with a Leadless Pacemaker.

Authors:  Yixin Kang; Cheng Ge; Huan Zhang; Saizhe Liu; Hongyang Guo; Junchang Cui
Journal:  Infect Drug Resist       Date:  2022-08-12       Impact factor: 4.177

4.  Update on the appropriate use of linezolid in clinical practice.

Authors:  Roberto Manfredi
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.